Drug Fix: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS
Citeline Podcasts
English - March 24, 2023 18:03 - 37 minutes - 22.7 MB - ★★★★★ - 24 ratingsBusiness News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.
More on these topics from The Pink Sheet:
Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs
https://pink.pharmaintelligence.informa.com/PS147930/Moderna-CEO-Hearing-Highlights-Dissatisfaction-With-Patient-Assistance-Programs
Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing
https://pink.pharmaintelligence.informa.com/PS147939/Moderna-CEO-Reminds-People-About-Value-Of-Government-Negotiations-At-Senate-Hearing
After Xtandi, Will Government Ever Seek March-In Rights Over Drug Pricing?
https://pink.pharmaintelligence.informa.com/PS147929/After-Xtandi-Will-Government-Ever-Seek-MarchIn-Rights-Over-Drug-Pricing
Xtandi Still Faces Likely US Price Cut Even As It Avoids ‘March In’ Proceeding
https://pink.pharmaintelligence.informa.com/PS147940/Xtandi-Still-Faces-Likely-US-Price-Cut-Even-As-It-Avoids-March-In-Proceeding
Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS
https://pink.pharmaintelligence.informa.com/PS147918/Accelerated-Approval-Is-US-FDA-Panels-Preferred-Path-For-BiogenIoniss-Tofersen-In-ALS
Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review
https://pink.pharmaintelligence.informa.com/PS147937/Accelerated-Approval-Potential-Sources-Of-Confirmatory-Evidence-Weighed-At-Tofersen-Review